The purpose of this study is to evaluate progression-free survival (PFS) with XL 184 treatment as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive either XL 184 or placebo in a 2:1 ratio. XL 184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
(Minimal Requirements) Please contact us for a full list of criteria.
Confirmed diagnosis of MTC that is measurable or non-measurable per mRECIST.
Patient must be at least 18 years of age or older.